Volume 13 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Guo Hui. Diagnostic criteria and research progress on lung allograft pathology[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 19-31. doi: 10.3969/j.issn.1674-7445.2022.01.004
Citation: Guo Hui. Diagnostic criteria and research progress on lung allograft pathology[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 19-31. doi: 10.3969/j.issn.1674-7445.2022.01.004

Diagnostic criteria and research progress on lung allograft pathology

doi: 10.3969/j.issn.1674-7445.2022.01.004
More Information
  • Corresponding author: Guo Hui, E-mail: zcguo@tjh.tjmu.edu.cn
  • Received Date: 2021-11-23
    Available Online: 2022-01-12
  • Publish Date: 2022-01-15
  • In recent years, the quantity of lung transplantation has been gradually increased in China along with the accumulation of surgical techniques and postoperative management experience of lung transplantation. Multiple lung allograft complications may occur after lung transplantation, mainly including primary graft dysfunction (PGD) caused by ischemia-reperfusion injury (IRI) of the lung allograft, acute and chronic rejection, opportunistic infection or lymphoproliferative disorder of lymphoid tissues induced by the decrease of host immunity due to postoperative use of immunosuppressants, etc. The diagnosis of complications after lung transplantation mainly relies on biopsy of the lung allograft. In this article, the brief history of lung allograft pathology, main approaches and pathological processing techniques of lung allograft biopsy, major complications after lung transplantation and pathological diagnostic criteria were elucidated, aiming to provide reference for targeted management of these complications in clinical practice.

     

  • loading
  • [1]
    STEWART S, FISHBEIN MC, SNELL GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection[J]. J Heart Lung Transplant, 2007, 26(12): 1229-1242. DOI: 10.1016/j.healun.2007.10.017.
    [2]
    胡春晓, 李小杉, 卫栋, 等. 前进中的肺移植事业——我国肺移植发展现状及未来[J]. 器官移植, 2020, 11(2): 204-207. DOI: 10.3969/j.issn.1674-7445.2020.02.005.

    HU CX, LI XS, WEI D, et al. The development of lung transplantation: current situation and future of lung transplantation in China[J]. Organ Transplant, 2020, 11(2): 204-207. DOI: 10.3969/j.issn.1674-7445.2020.02.005.
    [3]
    陈实, 郭晖. 移植病理学[M]. 北京: 人民卫生出版社, 2009.
    [4]
    朱艳红, 陈静瑜, 杨国仪, 等. 纤维支气管镜肺活检对肺移植术后急慢性排斥的诊断价值[J]. 中国危重病急救医学, 2009, 21(2): 119-120. DOI: 10.3760/cma.j.issn.1003-0603.2009.02.021.

    ZHU YH, CHEN JY, YANG GY, et al. Diagnostic value of transbronchial lung biopsies for acute and chronic rejection in lung transplant recipients[J]. Chin Crit Care Med, 2009, 21(2): 119-120. DOI: 10.3760/cma.j.issn.1003-0603.2009.02.021.
    [5]
    CAVAZZA A, COLBY TV, DUBINI A, et al. Transbronchial cryobiopsy in the diagnosis of diffuse lung disease[J]. Surg Pathol Clin, 2020, 13(1): 197-208. DOI: 10.1016/j.path.2019.11.004.
    [6]
    MALDONADO F, DANOFF SK, WELLS AU, et al. Transbronchial cryobiopsy for the diagnosis of interstitial lung diseases: chest guideline and expert panel report[J]. Chest, 2020, 157(4): 1030-1042. DOI: 10.1016/j.chest.2019.10.048.
    [7]
    中华医学会呼吸病学分会介入呼吸病学学组, 中国医师协会呼吸医师分会介入呼吸病学工作委员会. 经支气管冷冻活检技术临床应用专家共识[J]. 中华结核和呼吸杂志, 2019, 42(6): 405-412. DOI: 10.3760/cma.j.issn.1001-0939.2019.06.002.

    Interventional Respiratory Medicine Group of Respiratory Medicine Branch of Chinese Medical Association, Interventional Respiratory Medicine Working Committee of Respiratory Physician Branch of Chinese Medical Doctor Association. Expert consensus on clinical application of transbronchial cryobiopsy[J]. Chin J Tuberc Respir Dis, 2019, 42(6): 405-412. DOI: 10.3760/cma.j.issn.1001-0939.2019.06.002.
    [8]
    FROST AE, JAMMAL CT, CAGLE PT. Hyperacute rejection following lung transplantation[J]. Chest, 1996, 110(2): 559-562. DOI: 10.1378/chest.110.2.559.
    [9]
    SCORNIK JC, ZANDER DS, BAZ MA, et al. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry[J]. Transplantation, 1999, 68(10): 1542-1546. DOI: 10.1097/00007890-199911270-00018.
    [10]
    BITTNER HB, DUNITZ J, HERTZ M, et al. Hyperacute rejection in single lung transplantation--case report of successful management by means of plasmapheresis and antithymocyte globulin treatment[J]. Transplantation, 2001, 71(5): 649-651. DOI: 10.1097/00007890-200103150-00012.
    [11]
    MASSON E, STERN M, CHABOD J, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies[J]. J Heart Lung Transplant, 2007, 26(6): 642-645. DOI: 10.1016/j.healun.2007.03.007.
    [12]
    DE JESUS PEIXOTO CAMARGO J, MARCANTONIO CAMARGO S, MARCELO SCHIO S, et al. Hyperacute rejection after single lung transplantation: a case report[J]. Transplant Proc, 2008, 40(3): 867-869. DOI: 10.1016/j.transproceed.2008.02.052.
    [13]
    CAMPO-CAÑAVERAL DE LA CRUZ JL, NARANJO JM, SALAS C, et al. Fulminant hyperacute rejection after unilateral lung transplantation[J]. Eur J Cardiothorac Surg, 2012, 42(2): 373-375. DOI: 10.1093/ejcts/ezs066.
    [14]
    DIAMOND JM, PORTEOUS MK, ROBERTS LJ 2ND, et al. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia[J]. J Heart Lung Transplant, 2016, 35(4): 500-507. DOI: 10.1016/j.healun.2015.12.012.
    [15]
    NATALINI JG, DIAMOND JM, PORTEOUS MK, et al. Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease[J]. J Heart Lung Transplant, 2021, 40(5): 351-358. DOI: 10.1016/j.healun.2021.01.1391.
    [16]
    LEVINE DJ, GLANVILLE AR, ABOYOUN C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2016, 35(4): 397-406. DOI: 10.1016/j.healun.2016.01.1223.
    [17]
    ROUX A, BENDIB LE LAN I, HOLIFANJANIAINA S, et al. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics[J]. Am J Transplant, 2016, 16(4): 1216-1228. DOI: 10.1111/ajt.13589.
    [18]
    ROUX A, THOMAS KA, SAGE E, et al. Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study[J]. Transpl Int, 2018, 31(7): 761-772. DOI: 10.1111/tri.13149.
    [19]
    BERY AI, HACHEM RR. Antibody-mediated rejection after lung transplantation[J]. Ann Transl Med, 2020, 8(6): 411. DOI: 10.21037/atm.2019.11.86.
    [20]
    HACHEM RR. The role of the immune system in lung transplantation: towards improved long-term results[J]. J Thorac Dis, 2019, 11(Suppl 14): S1721-S1731. DOI: 10.21037/jtd.2019.04.25.
    [21]
    WALLACE WD, LI N, ANDERSEN CB, et al. Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies[J]. J Heart Lung Transplant, 2016, 35(1): 40-48. DOI: 10.1016/j.healun.2015.08.021.
    [22]
    GLANVILLE AR, VERLEDEN GM, TODD JL, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-a consensus report from the Pulmonary Council of the ISHLT[J]. J Heart Lung Transplant, 2019, 38(5): 483-492. DOI: 10.1016/j.healun.2019.03.008.
    [23]
    YOSHIYASU N, SATO M. Chronic lung allograft dysfunction post-lung transplantation: the era of bronchiolitis obliterans syndrome and restrictive allograft syndrome[J]. World J Transplant, 2020, 10(5): 104-116. DOI: 10.5500/wjt.v10.i5.104.
    [24]
    ONISHI Y, KAWAMURA T, HIGASHINO T, et al. Clinical features of acute fibrinous and organizing pneumonia: an early histologic pattern of various acute inflammatory lung diseases[J]. PLoS One, 2021, 16(4): e0249300. DOI: 10.1371/journal.pone.0249300.
    [25]
    YATES B, MURPHY DM, FORREST IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome[J]. Am J Respir Crit Care Med, 2005, 172(6): 772-775. DOI: 10.1164/rccm.200411-1537OC.
    [26]
    VERLEDEN SE, VANDERMEULEN E, RUTTENS D, et al. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS)[J]. Semin Respir Crit Care Med, 2013, 34(3): 352-360. DOI: 10.1055/s-0033-1348463.
    [27]
    TODD JL, KELLY FL, NAGLER A, et al. Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation[J]. Am J Transplant, 2020, 20(3): 825-833. DOI: 10.1111/ajt.15667.
    [28]
    SACREAS A, TAUPIN JL, EMONDS MP, et al. Intragraft donor-specific anti-HLA antibodies in phenotypes of chronic lung allograft dysfunction[J]. Eur Respir J, 2019, 54(5): 1900847. DOI: 10.1183/13993003.00847-2019.
    [29]
    LOOR K, PALLISA E, CULEBRAS M, et al. New opacities in lung allograft after transbronchial cryobiopsy[J]. Respir Med, 2020, 170: 106043. DOI: 10.1016/j.rmed.2020.106043.
    [30]
    VANSTAPEL A, GOLDSCHMEDING R, BROEKHUIZEN R, et al. Connective tissue growth factor is overexpressed in explant lung tissue and broncho-alveolar lavage in transplant-related pulmonary fibrosis[J]. Front Immunol, 2021, 12: 661761. DOI: 10.3389/fimmu.2021.661761.
    [31]
    WEIGT SS, WANG X, PALCHEVSKIY V, et al. Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection[J]. J Heart Lung Transplant, 2019, 38(8): 845-855. DOI: 10.1016/j.healun.2019.05.001.
    [32]
    KOUTSOKERA A. Rethinking bronchoalveolar lavage in acute cellular rejection: how golden is the standard of transbronchial biopsies?[J]. J Heart Lung Transplant, 2019, 38(8): 856-857. DOI: 10.1016/j.healun.2019.06.016.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(2)

    Article Metrics

    Article views (474) PDF downloads(132) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return